|
Title Bifidogenic Effects of a Unique Synbiotic Mixture (Scgos/Lcfos and Bifidobacterium Breve M-16V) In Healthy Infants |
|
Type Poster Presentation |
|
Theme Probiotics and Prebiotics: Excellence in Science and Clinical Translation |
|
Topic Probiotic and Prebiotic Clinical Research, From Newborns to Elderly |
|
Main Author Nopaorn Phavichitr2 |
|
Presenting Author Shugui Wang1 |
|
Co-Author Shugui Wang1 Sukkrawan Intarakhao3 Rocio Martin1 Ruangvith Tantibhaedhyangkul2 Sirinuch Chomto6 Jan Knol4 5 Sungkom Jongpiputvanich6 COLOR Study Group |
|
Department / Institution / Country Nutricia Research / Danone / Singapore1 Department of Pediatrics / Phramongkutklao Hospital / Thailand (ไทย)2 Department of Pediatrics / Thammasat Hospital / Thailand (ไทย)3 Nutricia Research / Danone / Netherlands4 Laboratory of Microbiology / Wageningen University / Netherlands5 Department of Pediatrics / King Chulalongkorn Memorial Hospital / Thailand (ไทย)6 |
|
Background and Rationale Human milk from healthy mothers is considered the optimal nutrition for infants and contains about 104 viable bacteria. It is one of the bacterial sources to seed the infant’s gut which is normally dominated by infant-type Bifidobacterium species such as B. breve. Bacteria like bifidobacteria play a key role in gut health and immune maturation during early life. However, not all infants are dominated by bifidobacteria and some are even devoid of them. Infants born by C-section or with antibiotics administration during early life have compromised microbiome development. Synbiotics containing Bifidobacterium species can be used to increase the level of bifidobacteria in the infant’s gut. |
|
Objectives: Indicates the purpose of the study The aim of the study was to evaluate the effects of two different doses of synbiotics on bifidogenic effects in healthy infants. |
|
Methodology: Describe pertinent experimental procedures An exploratory, multi-centre randomised, double-blind, controlled study was conducted in Thailand in 290 healthy infants aged from 2-5 months. Infants, who were exclusively formula-fed for at least two weeks were recruited. After 2 weeks run-in period, infants were then randomized to receive either control product or one of the investigational products (containing 0.8g/100 ml scGOS/lcFOS with B. breve M-16V at a dose of either 1x 104 cfu/ml (Syn4) or 1x106 cfu/ml (Syn6)). Exclusively breast-fed infants were included as a reference. |
|
Results: Summarize the results of the research Syn4 and Syn6 significantly increased not only the total bifidobacteria proportion but also the prevalence and genomic copy numbers of B. breve and B. breve M-16V in healthy infants when compared with control group. |
|
Conclusions: State the main conclusions An infant-type Bifidobacterium, B. breve M-16V combined with scGOS/lcFOS (9:1) at a level close to the level of bacteria in human milk, increased infant type Bifidobacterium species in infants. This relatively low dose of viable bacteria may be a suitable approach to support the normal development of the gut microbiome in healthy infants during early life. |